Search

Your search keyword '"Langley, David R."' showing total 249 results

Search Constraints

Start Over You searched for: Author "Langley, David R." Remove constraint Author: "Langley, David R."
249 results on '"Langley, David R."'

Search Results

4. Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry

9. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A

10. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers

11. Structure-based amelioration of PXR transactivation in a novel series of macrocyclic allosteric inhibitors of HIV-1 integrase

13. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

17. DNA-Model-Based Design and Execution of Some Fused Benzodiazepine Hybrid Payloads for Antibody–Drug Conjugate Modality

19. Design, Synthesis, and Structure–Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody–Drug Conjugates

20. Discovery and Optimization of Novel Pyrazolopyrimidines as Potent and Orally Bioavailable Allosteric HIV-1 Integrase Inhibitors

22. Some Recent Developments in the Synthesis and Structure-Activity Relationship of Novel Taxanes

23. Sequential 1H, 13C, and 15N NMR assignments and solution conformation of apokedarcidin

24. Chemistry and structure elucidation of the kedarcidin chromophore

25. Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy

26. A General Amino Acid Synthesis Enabled by Innate Radical Cross-Coupling

27. Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action

28. Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir

29. Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir

30. Communication: Quantum polarized fluctuating charge model: A practical method to include ligand polarizability in biomolecular simulations.

32. Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core

33. The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors

34. Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529

35. A Functional NaV1.7-NaVAb Chimera with a Reconstituted High-Affinity ProTx-II Binding Site

36. Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors

38. Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir

39. Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors

40. Characterizations of HCV NS5A replication complex inhibitors

41. Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment. 12. Structure–Activity Relationships Associated with 4-Fluoro-6-azaindole Derivatives Leading to the Identification of 1-(4-Benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248)

43. Isolation, structure determination, and proposed mechanism of action for artifacts of maduropeptin chromophore

46. Cloning, purification, crystallization and preliminary X-ray analysis of the catalytic domain of human receptor-like protein tyrosine phosphatase γ in three different crystal forms

47. In Vivo Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043

Catalog

Books, media, physical & digital resources